About surrozen inc - SRZN
Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.
SRZN At a Glance
Surrozen, Inc.
171 Oyster Point Boulevard
South San Francisco, California 94080
| Phone | 1-650-489-9000 | Revenue | 3.48M | |
| Industry | Biotechnology | Net Income | -242,026,000.00 | |
| Sector | Health Technology | Employees | 44 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SRZN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 48.606 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.079 |
| Enterprise Value to Sales | 24.848 |
| Total Debt to Enterprise Value | 0.077 |
SRZN Efficiency
| Revenue/Employee | 79,022.727 |
| Income Per Employee | -5,500,590.909 |
| Receivables Turnover | 16.716 |
| Total Asset Turnover | 0.047 |
SRZN Liquidity
| Current Ratio | 9.22 |
| Quick Ratio | 9.22 |
| Cash Ratio | 8.987 |
SRZN Profitability
| Gross Margin | 84.556 |
| Operating Margin | -1,210.584 |
| Pretax Margin | -6,960.771 |
| Net Margin | -6,960.771 |
| Return on Assets | -328.855 |
| Return on Equity | N/A |
| Return on Total Capital | 133.625 |
| Return on Invested Capital | N/A |
SRZN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -3.665 |
| Total Debt to Total Assets | 6.725 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -2.953 |